<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04762745</url>
  </required_header>
  <id_info>
    <org_study_id>RRMM-01</org_study_id>
    <nct_id>NCT04762745</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the efficacy and safety of pomalidomide and bendamustine with dexamethasone in&#xD;
      relapsed or refractory multiple myeloma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial has two parts: firstly, to explore the maximum tolerated dosage(MTD) of&#xD;
      bendamustine in the combination of pomalidomide and dexamethasone in relapsed or refractory&#xD;
      multiple myeloma; secondly, to find out efficacy and safety of pomalidomide and bendamustine&#xD;
      with dexamethasone in relapsed or refractory multiple myeloma in an expanded cohort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>At the end of Cycle 8 in Phase II (each cycle is 28 days)</time_frame>
    <description>The number of patients achieving partial response (PR), very good partial response (VGPR), complete response (CR) or stringent complete response (sCR) after 8 cycles in phase II.&#xD;
sCR = CR as defined in Primary Outcome measure 2 plus normal free light chain ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.&#xD;
CR- Negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and &lt; 5% plasma cells in bone marrow.&#xD;
VGPR = Serum and urine M-protein detectable by immunofixation but not on electrophoresis or &gt; 90% reduction in serum M-protein plus urine M-protein level &lt; 100 mg/24 h.&#xD;
PR- &gt; 50% reduction of serum M-protein and urine M-protein by &gt;90% or to &lt; 200 mg/24 h In addition, if present at baseline, a &gt; 50% reduction in the size of soft tissue plasmacytomas is also required.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response(CR) and stringent complete response(sCR) rate</measure>
    <time_frame>At the end of Cycle 8 in Phase II (each cycle is 28 days)</time_frame>
    <description>The CR and sCR rate after 8 cycles in phase II.&#xD;
CR- Negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and &lt; 5% plasma cells in bone marrow.&#xD;
sCR = CR as defined in Primary Outcome measure 2 plus normal free light chain ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
    <description>The time relapsed for patients between initiation of study therapy and either disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Through study completion, up to 2 years</time_frame>
    <description>Number of participants with treatment-related adverse events during the study period as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Relapsed, Refractory, Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Phase I, Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The combination of bendamustine, 60mg/m2, with pomalidomide and dexamethasone will be administrated in 6 relapsed or refractory multiple myeloma patients for 1 cycle. If dose limiting toxicity (DLT) is observed in 2 or more of the six patients at the same dosing level while DLT is observed in only 1 or none of the 6 patients at the dosing level immediately below it, then the lower dosing level will be defined as the maximum tolerated dose (MTD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I, Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The combination of bendamustine, 70mg/m2, with pomalidomide and dexamethasone will be administrated in 6 relapsed or refractory multiple myeloma patients for 1 cycle. If dose limiting toxicity (DLT) is observed in 2 or more of the six patients at the same dosing level while DLT is observed in only 1 or none of the 6 patients at the dosing level immediately below it, then the lower dosing level will be defined as the maximum tolerated dose (MTD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I, Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The combination of bendamustine, 80mg/m2, with pomalidomide and dexamethasone will be administrated in 6 relapsed or refractory multiple myeloma patients for 1 cycle. If dose limiting toxicity (DLT) is observed in 2 or more of the six patients at the same dosing level while DLT is observed in only 1 or none of the 6 patients at the dosing level immediately below it, then the lower dosing level will be defined as the maximum tolerated dose (MTD).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The combination of MTD dosage of bendamustine with pomalidomide and dexamethasone will be administrated in an expanded relapsed or refractory multiple myeloma cohorts for 8 cycles, then under the combination of pomalidomide and dexamethasone as maintenance therapy until progression or intolerable toxicities.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 1cycle.</description>
    <arm_group_label>Phase I, Cohort 1</arm_group_label>
    <other_name>Pomalidomide( Anyue®, Chia Tai TIANQING, China)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Bendamustine( Leweixin®, Chia Tai TIANQING, China), 60mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 1 cycle.</description>
    <arm_group_label>Phase I, Cohort 1</arm_group_label>
    <other_name>Bendamustine( Leweixin®, Chia Tai TIANQING, China)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 1 cycle.</description>
    <arm_group_label>Phase I, Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 1cycle.</description>
    <arm_group_label>Phase I, Cohort 2</arm_group_label>
    <other_name>Pomalidomide( Anyue®, Chia Tai TIANQING, China)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Bendamustine( Leweixin®, Chia Tai TIANQING, China), 70mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 1 cycle.</description>
    <arm_group_label>Phase I, Cohort 2</arm_group_label>
    <other_name>Bendamustine( Leweixin®, Chia Tai TIANQING, China)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 1 cycle.</description>
    <arm_group_label>Phase I, Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 1cycle.</description>
    <arm_group_label>Phase I, Cohort 3</arm_group_label>
    <other_name>Pomalidomide( Anyue®, Chia Tai TIANQING, China)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Bendamustine( Leweixin®, Chia Tai TIANQING, China), 70mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 1 cycle.</description>
    <arm_group_label>Phase I, Cohort 3</arm_group_label>
    <other_name>Bendamustine( Leweixin®, Chia Tai TIANQING, China)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 1 cycle.</description>
    <arm_group_label>Phase I, Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle, 8 cycles. Then pomalidomide( Anyue®, Chia Tai TIANQING, China), 4mg, orally(PO), d1-21, 28d/cycle until progression or intolerable toxicities.</description>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>Pomalidomide( Anyue®, Chia Tai TIANQING, China)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Bendamustine( Leweixin®, Chia Tai TIANQING, China), 70mg/m2/d, intravenously(IV), d1-2, 28d/cycle, 8 cycles.</description>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>Bendamustine( Leweixin®, Chia Tai TIANQING, China)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle, 8 cycles. Then dexamethasone, 40mg, PO or IV, d1, 8, 15, 22, 28d/cycle until progression or intolerable toxicities.</description>
    <arm_group_label>Phase II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of 18-75, no gender limitations.&#xD;
&#xD;
          -  Ability of contraception during the experiment, no matter if they have suffered from&#xD;
             infertility.&#xD;
&#xD;
          -  Relapsed or refractory to prior lenalidomide or/and bortezomib(either in combination&#xD;
             or sequential)therapy (i.e. history of progression on therapy or within 60 days after&#xD;
             completion)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2, life expectancy&#xD;
             of more than 6 months.&#xD;
&#xD;
          -  Measurable disease:&#xD;
&#xD;
        Serum M protein &gt; 10 g/L or Urine M protein ≥200 mg/24 hr or Elevated Free Light Chain per&#xD;
        International Myeloma Working Group (IMWG) criteria, and abnormal ratio.&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;1.0 x 109/L or &gt;1.0 x 109/L due to&#xD;
             granulocyte/macrophage colony stimulating factor (GCSF and GMCSF), or if &gt;50% marrow&#xD;
             involvement, there is no limitations&#xD;
&#xD;
          -  Platelet count &gt;50.0 x 109/L or if &gt;50% marrow involvement, there is no limitations.&#xD;
&#xD;
          -  Total bilirubin ≤ 2.0mg/dL, and aspartate aminotransferase (AST) and alanine&#xD;
             aminotransferase (ALT) &lt; 3 times the upper limit of normal.&#xD;
&#xD;
          -  Serum creatinine ≤2.0 mg/dL or creatinine clearance ≥60ml/min.&#xD;
&#xD;
          -  Agree to take anticoagulant drugs, included but not limited to aspirin.&#xD;
&#xD;
          -  Agree to sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known sensitivity to pomalidomide or bendamustine or dexamethasone and&#xD;
             their accessories.&#xD;
&#xD;
          -  Patients with primary systemic amyloidosis or monoclonal gammopathy of undetermined&#xD;
             significance or smoldering multiple myeloma.&#xD;
&#xD;
          -  Patients with active new thrombosis or disagree to take anticoagulant drugs, included&#xD;
             but not limited to aspirin.&#xD;
&#xD;
          -  Active treatment or intervention for other malignancy or need active treatment within&#xD;
             4 weeks of starting study treatment. Patients with nonmelanoma skin cancer or&#xD;
             carcinoma in situ of any type are not excluded if they have undergone complete&#xD;
             resection.&#xD;
&#xD;
          -  Central nervous system involvement.&#xD;
&#xD;
          -  Systemic treatment with immunodepressants or steroids.&#xD;
&#xD;
          -  Ongoing or active systemic infection, active hepatitis B virus infect, active&#xD;
             hepatitis C infection, or known human immunodeficiency virus (HIV) positive&#xD;
&#xD;
          -  Evidence of current uncontrolled cardiovascular conditions, including uncontrolled&#xD;
             hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart&#xD;
             failure(NT-Pro-BNP≥1800pg/mL), unstable angina, or myocardial infarction within the&#xD;
             past 6 months.&#xD;
&#xD;
          -  Infection requiring systemic antibiotic therapy or other serious infection.&#xD;
&#xD;
          -  Comorbid systemic illnesses or other severe concurrent disease which, in the judgment&#xD;
             of the investigator, would make the patient inappropriate for entry into this study or&#xD;
             interfere significantly with the proper assessment of safety and toxicity of the&#xD;
             prescribed regimens. Psychiatric illness/social situation that would limit compliance&#xD;
             with study requirements.&#xD;
&#xD;
          -  Under other clinical trial procedures.&#xD;
&#xD;
          -  Female patients who are lactating or pregnant.&#xD;
&#xD;
          -  Other patients not appropriate for the trial in the judgment of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Please Select</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 17, 2021</last_update_submitted>
  <last_update_submitted_qc>February 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hua Wang</investigator_full_name>
    <investigator_title>Associate professor of Department of Hematological Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China</investigator_title>
  </responsible_party>
  <keyword>pomalidomide, bendamustine, multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

